Understanding the ins and outs of a rare disease like atypical hemolytic uremic syndrome (aHUS) is a difficult task for ...
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
A securities class action against Alexion Pharmaceuticals Inc. was “related” to an SEC investigation and should have been ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...
DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of pipeline dry AMD therapies in various stages of clinical development, major ...
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback